Genetic and Environmental Factors Associated With Type 2 Diabetes and Diabetic Vascular Complications

Mariana Murea, Lijun Ma, and Barry I. Freedman

Department of Internal Medicine, Section on Nephrology, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA.
Address correspondence to: Mariana Murea, e-mail: mmurea@wakehealth.edu

Manuscript submitted December 20, 2011; resubmitted January 18, 2012; accepted January 25, 2012

Abstract

Faced with a global epidemic of type 2 diabetes (T2D), it is critical that researchers improve our understanding of the pathogenesis of T2D and related vascular complications. These findings may ultimately lead to novel treatment options for disease prevention or delaying progression. Two major paradigms jointly underlie the development of T2D and related coronary artery disease, diabetic nephropathy, and diabetic retinopathy. These paradigms include the genetic risk variants and behavioral/environmental factors. This article systematically reviews the literature supporting genetic determinants in the pathogenesis of T2D and diabetic vasculopathy, and the functional implications of these gene variants on the regulation of beta-cell function and glucose homeostasis. We update the discovery of diabetes and diabetic vasculopathy risk variants, and describe the genetic technologies that have uncovered them. Also, genomic linkage between obesity and T2D is discussed. There is a complementary role for behavioral and environmental factors modulating the genetic susceptibility and diabetes risk. Epidemiological and clinical data demonstrating the effects of behavioral and novel environmental exposures on disease expression are reviewed. Finally, a succinct overview of recent landmark clinical trials addressing glycemic control and its impact on rates of vascular complications is presented. It is expected that novel strategies to exploit the gene- and exposure-related underpinnings of T2D will soon result.

Keywords: type 2 diabetes · gene · environment · vascular complications · polymorphism · heritability · GWAS · linkage analysis

Morbidity and mortality associated with type 2 diabetes

The prevalence of type 2 diabetes (T2D) has been steadily rising in recent decades. Worldwide, the number of diagnosed diabetes cases reached 30 million in 1985, 135 million in 1995, 366 million in 2011, and is predicted to reach 552 million by 2030. The prevalence of T2D vastly exceeds that of type 1 diabetes, accounting for up to 90% of all diabetes cases (http://diabetes.niddk.nih.gov/dm/pubs/statistics/index.aspx#fast, accessed February, 2012).

Diabetes is the seventh leading cause of death in the United States. Compared with the general non-diabetic population, persons with diabetes have approximately a 7-year shorter life expectancy, an effect directly related to the major diabetic complications [1]. Patients with diabetes develop macrovascular complications (including coronary artery disease (CAD), peripheral vascular disease, and stroke) and microvascular complications (including diabetic nephropathy (DN), diabetic retinopathy (DR), and peripheral neuropathy), which are collectively known as diabetic vascular complications. Worldwide, diabetes is the major cause of CAD, limb amputations, end-stage
renal disease (ESRD), and blindness. Compared to non-diabetic individuals, adults with diabetes have a 2-4-fold higher death rate from CAD, and those with ESRD on dialysis have a 4-fold reduction in life expectancy [2, 3]. A recent study investigated the association of diabetes with a broad range of health conditions. People with diabetes had a 25-75% higher risk of dying from cancer, infections, liver disease, lung disease, mental disorders, intentional self-harm, external causes, and falls, independent of other risk factors (such as age, gender, smoking, and weight). Overall, approximately 40% of the excess deaths in diabetic patients appears to be due to non-vascular events [4].

Classification of type 2 diabetes

Recent advances in molecular and genetic research have enabled a classification of T2D into clinical sub-phenotypes of various pathophysiology. A small fraction of all diabetes cases (1-5%), termed maturity-onset diabetes of the young (MODY), occur as a result of single-gene mutations impacting the ability of the pancreatic \(\beta\)-cells to produce or secrete insulin [5]. Diabetes can also develop secondary to a specific disease or as a result of exogenous factors such as:

- medications (e.g., corticosteroids, calcineurin inhibitors, thiazide diuretics, antipsychotics, HIV protease inhibitors, statins),
- viral infections (e.g., hepatitis C), and
- hormonal factors, including pregnancy and oral contraceptives [6].

These types can be classified as “other specific types of diabetes”. Notably, only a subset of individuals exposed to exogenous triggers develop diabetes.

Increased individual risk of diabetes may be explained by one or more of the following factors:

- Variable loads of adverse environmental exposures.
- Congenitally reduced pancreatic beta-cell mass.
- Host genetic susceptibility.

The most prevalent form of diabetes, T2D per se, accounts for more than 80% of diagnosed cases. It represents a heterogenous entity which does not include type 1 diabetes, genetic forms of MODY, gestational diabetes, or other specific types secondary to specific diseases or exposures [6]. It is generally agreed that T2D is a multifactorial disease,
arising from the presence of T2D risk alleles in multiple genes and a disease-conducive environment. Environmental factors modulating genetic risk are proving to be important in the development of T2D.

Heritability and environment in type 2 diabetes

Several lines of evidence support the principle of inherited genetic susceptibility as an important risk factor for common T2D. The offspring of a parent with T2D face a 40% life-time risk of developing T2D, increasing to 70% when both parents have T2D [7]. The mode of genetic transmission of common T2D, unlike monogenic diabetes, does not follow simple Mendelian patterns. Twin studies have assessed the relative importance of heredity and environment on the etiology of T2D. In a population-based cohort of twins in Finland, the cumulative concordance rate of T2D was clearly higher among monozygotic (MZ) twins (34% probandwise, 20% pairwise) than dizygotic (DZ) twins (16% probandwise, 8% pairwise), while the cumulative incidence of diabetes did not differ between MZ and DZ twins [8]. Importantly, this study applied threshold modeling techniques to estimate and compare the contribution of heritability, shared environmental, and unique environmental sources of variation in the underlying liability to T2D. Based on best fit models, heritability was 46%, shared environmental effects were 15%, and unshared environmental effects accounted for 38% of the liability for T2D [8].

The risk of T2D is higher in certain ethnic groups, independent of metabolic risk factor profiles. For example, Pima Indians have a 10-fold higher prevalence of T2D than the general U.S. population. Based on 2004-2006 national survey data for individuals 20 years of age or older, 6.6% of non-Hispanic whites, 7.5% of Asian Americans, 10.4% of Hispanic Americans, and 11.8% of non-Hispanic blacks had diagnosed T2D. (http://diabetes.niddk.nih.gov/dm/pubs/statistics/#Racial, accessed February, 2012). However, shared or unique environmental and genetic effects may be possible reasons for ethnic differences in susceptibility to T2D.

Finding the genetic determinants of common type 2 diabetes - methods, results, and functions

Genetic research tools have evolved significantly in recent decades. Table 1 contains the principal genetic methods and the presumed mechanism of action of the major genes reproducibly associated with T2D and related glycemic traits.

Candidate gene association studies and linkage analysis were the primary methods used to identify T2D susceptibility loci, prior to the application of genome-wide association studies (GWAS). In the candidate gene approach, genes were localized in pathways that were considered likely to be involved in the pathogenesis of diabetes, including PPAR-gamma (PPARG) and potassium inwardly rectifying channel subfamily J member 11 (KCNJ11). The protein products of these two genes are targeted by antidiabetic medications (thiazolidinediones and sulphonylureas) and were found to harbor missense mutations associated with T2D risk [9, 10].

<table>
<thead>
<tr>
<th>Study methodology</th>
<th>Functional effect</th>
</tr>
</thead>
<tbody>
<tr>
<td>Biological candidate gene</td>
<td>KCNJ11, HNF1A/1B, WFS1, GCK, TCF2</td>
</tr>
<tr>
<td>Genome-wide linkage scan (exploration of the linkage peaks)</td>
<td>TCF7L2, HNF4A, CAPN10</td>
</tr>
<tr>
<td>Genome-wide association scan</td>
<td>ADAMTS9, IRS1, FTO, GCKR, SREBF1, KLF14</td>
</tr>
</tbody>
</table>
Family-based linkage analyses have helped to identify causal mutations underpinning the Mendelian forms of diabetes in MODY [11]. Among families with common form of T2D, genome-wide linkage scans have identified several T2D linkage peaks on chromosomes 1q21, 10q25.3, and 20q13.3. The most replicated region across different cohorts and ethnic groups resides on chromosome 1q21-25 [12-17]. Further analysis of the chromosome 10 region showed that variants in the transcription factor 7-like 2 (TCF7L2) gene were strongly associated with T2D in multiple independent cohorts [18]. TCF7L2 is a component of the Wnt signaling pathway, and it is a transcriptional regulator involved in stimulating the proliferation of pancreatic β-cells, regulating embryonic development of the pancreatic mass, and controlling the production of the incretin hormone glucagon-like peptide-1 (GLP-1) in intestinal endocrine cells [19].

Major advancements in unveiling genetic determinants of T2D were made through GWAS, a methodology using single nucleotide polymorphism (SNP) markers across the genome. The outcomes of GWAS have helped in identifying novel pathways, and highlighted the role of β-cell dysfunction in T2D. The prevailing theory of the pathology of common T2D implicates an interplay of defective insulin secretion, defective insulin response (insulin resistance), and environmental factors (e.g., westernized food pattern, obesity, and sedentary lifestyle). Experimentally, excess adipose tissue and increased plasma free fatty acid levels disrupt insulin signal transduction and glucose uptake in insulin-sensitive tissues, a phenomenon termed lipotoxicity [20]. Obesity and diets rich in saturated fatty acids can induce T2D through β-cell endoplasmic reticulum stress and apoptosis [21]. Adipose tissue is also a source of circulating free fatty acids, cytokines, and other proteins that are mechanistically related to insulin resistance [22]. Although it was anticipated that T2D genetic markers would point toward genes with impacts on insulin action, most T2D risk alleles identified through GWAS have impacts on glucose-induced insulin secretion (ADAMTS9, ADCY5, CDC123, CAMK1D, CDKAL1, CDKN2A/B, CENTD2, DGKB/TMEM195, FOXO1, GCK, HHEX, IGF2BP2, KCNQ1, KCNJ11, MTNR1B, PROX1, SGK1, SLC30A8, TCF7L2, TSPAN8/LGR5, THADA). Only a few genes have effects on insulin resistance (FTO, GCKR, KLF14, PPARG, ADAMTS 9), and the functions of many associated variants remain unknown (Table 1) [23].

There has been much speculation about potential mechanisms by which gene polymorphisms affect insulin secretion. KCNJ11 and SGK1 encode or activate β-cell potassium channels, respectively. Polymorphisms in these genes may increase the probability of the channel opening or closing, and thereby impact the cellular mechanism of insulin secretion [24]. Experimentally, genetic variants of KCNQ1, TCF7L2, GIPR, and WFS1 can affect glucose-induced incretin hormone release in the intestine and incretin-stimulated insulin release in the pancreas [25].

It is also important to note that the glycemic phenotype can depend on the nature of genetic variation within and across different ethnic groups. Germline loss-of-function mutations in the PPARG gene have been detected in familial forms of diabetes where cases exhibit severe insulin resistance and hypertension [26]. In contrast, the widespread polymorphism (Pro12Ala allele) is protective against T2D in Caucasians, but not in South Asians [9, 27]. Similarly, different mutations in HNF4A or IPF1 can lead to either pancreatic agenesis (for homozygous dominant-negative frameshift mutation in IPF1), MODY (for heterozygous dominant-negative frameshift mutation in IPF1, or loss of function mutation in HNF4A), or late-onset diabetes (for missense mutations in IPF1 or HNF4A) [28-30]. Studies examining pre-diabetic glycemic traits (fasting insulin, fasting glucose, glucose, and insulin levels after glucose challenge) have identified that loci implicated in T2D susceptibility can also harbor variants that correlate with continuous glycemic traits. However, loci associated with elevated fasting blood glucose levels have not uniformly been associated with T2D, suggesting that elevations in fasting glucose do not necessarily herald future risk of T2D, and that the pathophysiologic mechanisms of pre-diabetes (elevated fasting blood glucose) may differ from those necessary to induce overt T2D [31]. In conclusion, severe mutations can cause marked β-cell dysfunction and monogenic diabetes with autosomal dominant Mendelian inheritance within the same gene; whereas, common polymorphisms can modulate the risk of impaired glucose tolerance and T2D.

**Type 2 diabetes and obesity - genetic ties**

Since the rising prevalence of common T2D paralleled that of obesity, it was assumed that the genomic signals found in T2D studies could broadly overlap with the genomic signals captured in obesity studies. However, only three replicated
loci have been found to be shared in both obesity and T2D (FTO, PREX1, and MTNR1B) (Figure 1). The GWAS associations between FTO and PREX1 polymorphism and T2D were driven by obesity, since statistical adjustment for body mass index (BMI) eliminated the associations with diabetes [32, 33]. On the other hand, common variants in melatonin receptor type 1 B gene (MTNR1B) are associated with the risk of T2D independent of BMI [34, 35]. Receptors for melatonin (MTNR1A and MTNR1B) are expressed in pancreatic islet cells, and carriers of the risk genotype exhibit impaired glucose-stimulated insulin secretion [36, 37].

As aforementioned, the Pro12Ala polymorphism in PPARG can modulate the risk of T2D, and functional differences between proline- and alanine-containing gene products have been identified. PPARG is a transcription factor with a pivotal role in adipogenesis. PPARG expression is increased in adipose tissue of obese subjects [38]. Individuals with Pro12Ala substitution in PPARG have lower BMI and improved insulin sensitivity. In vitro studies revealed that the protective Pro isoform has higher transcriptional activity [39]. These data suggest that the Pro12Ala variant may be a genetic factor that contribute to both obesity and insulin resistance.
The “missing heritability” in common type 2 diabetes

To date, GWAS have identified nearly 52 common risk variants that associate with T2D [40, 41]. However, most of the risk alleles detected by GWAS have weak impacts and are located in intronic (non-coding) segments of genes or within chromosomal regions that do not contain genes (gene deserts). Together, these genes capture only 10% of the estimated heritability in T2D. Barring the association of T2D with the transcription factor 7-like 2 gene (TCF7L2), with odds ratio (OR) of 1.4 (each risk allele increases risk of T2D by approximately 40%), the remaining T2D risk variants generally have odds ratios (ORs) well below 1.3. Moreover, statistical prediction models using nearly 20 susceptibility loci did not confer superior prediction of disease, compared to traditional metabolic risk factors [42-44]. An even more comprehensive analysis, based on 40 autosomal SNPs, captured only an additional 10% of T2D-prone individuals aged less than 50 years, compared with a prediction based only on clinical factors. These 40 SNPs did not provide superior predictive ability in individuals over age 50 [45]. A general statistical model based on risk variants, each with an OR of 1.3-1.5 per allele, suggested that 50 or more independent risk alleles would be necessary to predict disease development with nearly 90% accuracy [46].

In view of these complexities, the concept of “missing heritability” emerged along with novel hypotheses for the presence of other genetic determinants (common copy number variations (CNVs), rare variants), or the interplay of different factors (epistasis, gene-environment interaction), to account for the unexplained heritability [47]. For example, a DNA copy number variation at the leptin receptor (LEPR) gene locus is associated with metabolic syndrome-related traits and risk of T2D. Lower LEPR copy numbers related to higher fasting glucose; and LEPR expression in lymphoblastoid cell lines correlated with the number of CNVs [48]. However, a role for common CNVs in the risk of T2D remains unclear. A genome-wide CNV-typing array of 3,432 common polymorphic CNVs, covering nearly 90% of total CNVs with minor allele frequencies (MAF) >5%, was designed and applied to nearly 3,000 T2D cases and 2,000 non-diabetic controls in the Genome Structural Variation Consortium (GSV). The results revealed that a CNV locus in TSPAN8 was associated with T2D, which was previously identified by SNP GWAS. This suggests that T2D gene associations are more frequently driven by SNPs than CNVs [49].

By design, GWAS captures common allelic variants across the genome, occurring in more than 5% of the population. A shift in the focus has evolved towards the possible contribution of low frequency (>1% and <5% of the population) or rare frequency (<1% of the population) variants to account for the unexplained heritability. The prime technology for detecting rare variants is direct sequencing, which may:

1. target regions of interest defined by GWAS with strong and repeated replication,
2. sequence all protein-coding regions ("exomes"), or
3. sequence the entire genome [47].

It has also been proposed that gene-gene interactions between T2D susceptibility variants could be nonlinear (in terms of epistasis), and thus jointly increase the genetic effect. However, despite broad acceptance of this theory, it has been difficult to detect interactions between SNPs. A recent study exploring main and epistatic effects in 70,236 markers tagging common SNPs showed that, although there was a two-locus association at 79 SNP-pairs encompassing TCF7L2 SNP paired with variants in FTO, TSPAN8, and CDKL1 (Bonferroni-corrected p-value = 0.05), the actual joint two-locus effects could be attributed to single-locus association at TCF7L2 [50]. Nevertheless, it is assumed that a very strong single-locus effect could conceal multic locus findings. Therefore, it is necessary that methodological approaches undergo further developments to explore the epistatic phenomena.

Behavioral and environmental factors

Sedentary lifestyles and high-fat diets are behavioral factors conducive to the high prevalence of T2D. Two large randomized cohorts of lifestyle interventions (dietary modification, weight loss, and exercise) in overweight adults (mean BMI 31 kg/m²) with impaired glucose tolerance achieved 58% reduction in the incidence of diabetes. These results were directly associated with lifestyle changes and weight loss [51, 52]. Nevertheless, approximately 10% of overweight adults with impaired glucose tolerance progressed to T2D within 3 years in these studies, despite rigorous lifestyle modification. While these cases of T2D could be due to the presence of non-modifiable genetic risk factors, it led to the theory that earlier lifestyle in-
A recently discussed environmental risk factor for T2D is pollution. Epidemiological data indicate that chronic exposure to organic land pollutants (pesticides, herbicides) disturbs glucose metabolism and induces insulin resistance. A strong dose-dependent relationship between serum concentrations of organic pesticides (subclasses of organochlorine and non-dioxin-like polychlorinated biphenyls) and prevalence of diabetes has been demonstrated, with ORs up to 11.5 for prevalent diabetes among those with the highest percentiles of serum pesticide levels compared to those with undetectable levels [54]. Serum levels of organochlorine pesticides in the general (non-diabetic) population are associated with humoral markers of insulin resistance (homeostasis model assessment of insulin resistance (HOMA-IR) derived from fasting glucose and insulin levels). This association is stronger in overweight individuals with the highest serum pesticide concentration and absent in those with the lowest concentration [55]. Because of the lipophilic nature of the organic pollutants, obesity may serve as a storage compartment for these toxic chemicals which induce insulin resistance and T2D in a dose- and possibly time-dependent manner [56, 57]. These findings have biologic plausibility exemplified in several experimental models. Exposure to the herbicide atrazine (ATZ) can cause mitochondrial toxicity and promote obesity and insulin resistance, with even more detrimental effects observed when animals were fed a high-fat diet [58]. Pesticides can suppress the expression of functional glucose transporter proteins in several organs, providing a hypothetical mechanism for the observed link between these chemicals and insulin resistance [59].

Air pollutants have also been studied in relation to the prevalence of T2D. Exposure to traffic-related pollutants (particulate matter (PM) and nitrogen dioxide (NO₂)) is associated with higher incidence rates of T2D in a dose dependent manner. The risk is present predominantly in women. The highest exposures carry a >20% increase in T2D prevalence after adjusting for other risk covariates (e.g., obesity, population density, ethnicity, income, education, smoking, health insurance, and indicators of indoor pollutant exposures) [60-63]. Plausible mechanisms by which air pollutants contribute to the development of T2D include induction of inflammation in adipose tissue and insulin resistance, demonstrated to occur in animals exposed to PM [64].

Other chemical contaminants in food (dioxins and polychlorinated biphenyls (PCBs)) or water (arsenic), and occupational exposures to various toxins (N-nitroso compounds, benzene, polycyclic aromatic hydrocarbons, and solvents in the rubber industry, e.g. dioxins and talc among pulp and paper mill workers, tetrachloroethylene among dry-cleaning workers, and N-nitroso compounds in engine manufacturing workers) have been linked with excess risk of T2D and mortality from diabetes. However, these data remain inconclusive because of the limited number of studies, small samples, and possible publication biases (reviewed in reference [65]).

As oxidative stress plays a role in insulin resistance, it was hypothesized that antioxidants might confer protection against T2D [66]. An inverse association between serum carotenoids, plasma vitamin C, and plasma tocopherol concentrations (markers of fruit and vegetable intake, or dietary supplements) with T2D and impaired glucose metabolism has been detected [67-69]. Also, a direct relation between vitamin E and vitamin C intake and insulin sensitivity has been reported among healthy supplement users [70, 71].

A recent study employed a novel methodology akin to GWAS, whereby environmental factors purported to cause T2D (pesticides, heavy metals, consumption of dietary supplements) were modeled using a method termed "environment-wide association study" (EWAS). Significant risk associations were identified between higher systemic levels of the pesticide derivative heptachlor epoxide, polychlorinated biphenyl, and gammavtocopherol (vitamin E), and lower beta-carotene (vitamin A precursor) levels [72].

Gene-environment interactions

Evidence that environmental factors modulate phenotypic expression emerged from the Diabetes Prevention Program (DPP) [52]. This multi-ethnic cohort was designed to test the preventive effects of a lifestyle intervention (low-fat diet, exercise, and behavior modification) or medication (metformin) on progression to diabetes in high-risk individuals with impaired glucose tolerance. Remarkably, for every 6.9 or 13.9 persons enrolled in the lifestyle-intervention or metformin program, respectively, one case of T2D was prevented. This translates into a significant 58% and 31% reduc-
tion, respectively, in the incidence of T2D. In a post-hoc analysis genotyping nearly 3,500 participants for transcription factor 7-like 2 (TCF7L2) polymorphisms (rs12255372 and rs7903146), the effect of the risk-conferring genotype on progression to diabetes was at its peak in the placebo group (hazard ratio (HR) 1.81, \( p = 0.004 \)), less in the metformin group (HR 1.62, \( p = 0.04 \)), and the risk dissipated in the lifestyle-intervention group (HR 1.15, \( p = 0.60 \)). The results were similar among the homozygous carriers of either of the two risk alleles, indicating that a behavioral intervention can mitigate the risk conferred by the genetic background [73]. A more recent analysis included genotyping of up to 34 T2D risk loci in DPP participants to examine whether the preventive interventions maintained their effectiveness in those individuals with higher genetic risk burden based on the computation of a genetic risk score. Importantly, treatment with either metformin or lifestyle intervention was effective in reducing the risk of diabetes at any level of genetic risk, with a trend towards the possibility that lifestyle intervention is more effective in individuals with the highest genetic risk scores [74].

Gene-environment interactions can be defined as genetic effects on (disease) traits that differ in magnitude (and sometimes direction) across environmental contexts. In most GWAS studies, it is assumed that the genetic effects are equal across the spectrum of the environmental exposure (i.e., no interactions exist). If this assumption is incorrect, then clinically relevant genetic risk factors may be missed [75]. This is the case for ataxia-telangiectasia mutated (ATM) variants that were associated with glycemic response to metformin in T2D. Whereas, no existing GWAS has revealed a significant association between ATM variants and diabetes, inhibition of ATM attenuates the phosphorylation and activation of AMP-activated protein kinase in response to metformin [76].

**Heritability and environmental factors in diabetic vascular complications**

Genetic and environmental factors play important roles in the development of T2D and diabetic vascular complications (Figure 1).

**Coronary artery disease**

Family history of CAD adds to cardiovascular risk in patients with diabetes, implicating either shared environmental factors and/or genetic factors [77, 78]. Marked racial differences are seen in the prevalence of subclinical atherosclerosis, manifested by levels of coronary artery, thoracic aorta, and abdominal aorta calcified atherosclerotic plaque. Relative to European Americans (EAs), the prevalence and severity of coronary calcification are markedly lower in African Americans (AAs) (52% vs. 70%). The same applies to the prevalence and severity of aortic and thoracic calcification (63% vs. 80%, and 27% vs. 42%), when adjusted for multiple CV risk factors [79, 80]. Carotid artery intima-media thickness in families with T2D has an estimated heritability approximating 40%, and ethnicity (AA vs. EA) is an important predictor [81].

To date, the best validated genetic risk marker for CAD in the general population is the chromosome 9p21.3 locus. Individuals homozygous for the CAD risk allele on chromosome 9p21 have a 40% increased risk of CAD and an estimated risk of suffering myocardial infarction 1.64 times greater than non-carriers [82]. In a case-control study of nearly 1,200 T2D patients from two different cohorts, the 9p21 variant was associated with CAD risk, and the risk was increased by history of poor glycemic control [83]. Diabetic subjects with two 9p21 risk alleles have a doubled odds for CAD at adequate glycemic control, and quadrupled odds for CAD at poor glycemic control. Of interest, previous studies have shown that different SNPs at the chromosome 9p21.3 locus contribute to the risk of T2D (Figure 1) [84]. Since large-vessel atherosclerosis can precede the development of diabetes (unlike classical microvascular complications), it had long been postulated that both conditions may share common genetic and environmental traits (dyslipidemia, hypertension), rather than atherosclerosis being a complication of diabetes [85]. A recent large-scale case-control study in a Chinese population was the first to report that two SNPs (rs10811661-T and rs10757283-C) on the 9p21.3 locus contribute to both the risk of T2D (OR 1.23 and 1.30, respectively) and CAD (OR 1.19-1.18, respectively) [86].

Adiponectin is a hormone with anti-atherogenic and anti-inflammatory effects, and variants in the adiponectin gene (ADIPOQ) have been assessed for association with CAD in diabetics. Homozygotes of +276T allele have a 30-80% lower risk of CAD [87, 88], while homozygotes of allele -4034C have an approximately 60% increased risk of CAD [88]. However, other studies showed conflicting results, with either opposing effects of the +45G allele on CAD risk [87, 89], or the presence of early-onset CAD in association with SNP +276T [90]. No asso...
cation has been found between variants +4276T and +45G with the development of T2D, although allele -11377G may be a risk factor for T2D (OR 1.12, 95%CI 1.02-1.23, p = 0.009, dominant model) [91]. At the molecular level, atherosclerosis is characterized by chronic inflammation and activation of transcription factor nuclear factor-κB (NF-κB) [92]. Tumor necrosis factor induced protein 3 (TNFAIP3) is a cytoplasmic protein that limits inflammation by inhibition of NF-κB [93]. Polymorphisms in the TNFAIP3 gene were shown to be independently associated with CAD, with an adjusted OR of 2.3, and paradoxical higher OR of 3.9 in individuals with good glycemic control. Peripheral blood mononuclear cells carrying risk alleles had 30-45% lower mRNA TNFAIP3 levels [94]. In an attempt to explain this paradoxical finding, it was argued that cellular pathways mediating the increased risk of CAD in T2D may differ in the two glycemic states. While NF-κB-mediated mechanisms may be predominant in the presence of moderate hyperglycemia, it is speculated that other pathways may prevail in the presence of more severe hyperglycemia [94].

Diabetic nephropathy

It is generally accepted that there is a genetic susceptibility to DN. Albuminuria, chronic kidney disease (CKD), and ESRD segregate within diabetic families, but DN develops only in a subset of T2D-affected populations in all race groups [95, 96]. Also, there is a racial affinity with DN, which further underscores the presence of genetic and/or environmental risk factors. African Americans (AAs) with T2D have an approximately 40% higher risk of DN and 3 times higher rates of progression to ESRD, relative to European Americans (EAs) [97, 98]. Several genes have been reproducibly associated with DN susceptibility (Figure 1):

- erythropoietin (EPO),
- superoxide dismutase 1 (SOD1),
- 4.1 protein,
- ezrin,
- radixin,
- moesin (FERM) domain containing 3 (FRMD3),
- cysteinyl-tRNA synthetase (CARS),
- plasmacytoma variant translocation 1 (PVT1),
- engulfment and cell motility 1 (ELMO1),
- carnosinase 1 (CNDP1),
- carnosinase 2 (CNDP2),
- endothelial nitric oxide synthase (eNOS),
- acetyl-coenzyme A carboxylase beta (ACACB),
- protein kinase C beta 1 (PRKCB1),
- LIM domain kinase 2 (LIMK2),
- Sfi1 homolog,
- spindle assembly associated (SFI1), and
- ribosomal protein S12 (RPS12) [99-102].

The in vivo disease mechanisms driven by these polymorphisms are intensively studied. Similar to genetic pathways in the development of CAD, it can be theorized that some T2D mechanistic pathways may share a common pathogenesis with susceptibility to DN. For example, a single nucleotide polymorphism in the ACACB gene is strongly associated with albuminuria and advanced CKD in Asians and EAs [101, 103]. The gene product is the acetyl-CoA carboxylase beta enzyme, which is important in fatty acid oxidation. The latter is a cellular process implicated in insulin resistance via the mechanism of lipotoxicity [104]. Also, the protein kinase C isomorph zeta (PKC-zeta) gene modulates inflammatory pathways in adipose cells. PKC-zeta deficiency generates insulin resistance in vivo [105]. Polymorphisms in the PKC beta 1 (PKCB1) gene are associated with increased risk of ESRD in Chinese subjects with T2D [100]. The Pro12Ala polymorphism in the human peroxisome proliferator-activated receptor gamma (PPARG) gene is associated with improved insulin sensitivity, decreased risk of T2D, and lower levels of albuminuria and DN [106, 107].

Diabetic retinopathy

Although the risk of diabetic retinopathy (DR) increases with diabetes duration and poor glycemic control, some patients develop DR in spite of adequate glycemic control. Familial clustering of DR cases across different ethnicities suggests that genetic susceptibility may underlie this risk [108, 109]. The genetic heritability of DR in the FIND-Eye cohort was estimated at 25% [110]. Retinopathy develops in approximately 21% of patients newly diagnosed with T2D and in approximately 60% of patients with T2D within the first 2 decades after diagnosis [111]. There is a strong association between microalbuminuria and DR in persons with T2D. The prevalence of DR is doubled in patients with microalbuminuria, and 6 times higher in the presence of macroalbuminuria [112], suggesting that DN and DR may share common risk factors, including genetic susceptibility factors. Indeed, sev-
eral genes have been associated with DR and DN [113-115]. The pathophysiology of DR is complex, and involves the interplay of numerous molecular mediators, such as advanced glycation end products (AGEs), oxidative stress, neoangiogenesis, and activation of the polyol pathway. Accumulation of AGEs in diabetes affects the extracellular matrix and a variety of cellular functions implicated in diabetic vascular complications by engaging the receptor for advanced glycation end products (RAGE) [116]. Polymorphisms in the RAGE gene are associated with an increased risk of DR, particularly in East Asians [117, 118].

Oxidative stress plays an important role in the development of DR [119]. In this regard, it was investigated whether polymorphisms in the glutathione S-transferases M1 (GSTM1) and T1 (GSTT1) genes, encoding enzymes with a role in repairing endogenous compounds affected by oxidative stress, are associated with DR. A case-control study including 604 Caucasians with T2D found that deletion of GSTT1 was twice as common in T2D with DR than in diabetics without DR, while deletion of the GSTM1 was half as common in patients with DR [120]. Polymorphisms of the gene encoding the glyoxalase 1 (GLO1) enzyme that dispose endogenous toxins can also confer susceptibility to DR and DN [113]. Superoxide dismutase 2 (SOD2) is an enzyme with critical defense against oxidative stress. Several studies in different ethnic groups found that a polymorphism in the SOD2 gene confers protection from DR and DN [115]. Endothelial nitric oxide synthase (eNOS) and ischemia-induced retinal neovascularization also play a role in the pathogenesis of proliferative DR [121], and presence of the eNOS 4a/4a homozygous deletion was associated with a 3.4 times higher risk of PDR when adjusted for other risk factors [122].

Angiogenic factors such as vascular endothelial growth factor (VEGF) play a pivotal role in the pathogenesis of DR. Common polymorphisms in the promoter region, 5'-untranslated region (UTR)

### Table 2. Baseline characteristics and vascular outcomes stratified by tight (T) and conventional (C) glycemic control

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Participants (n)</td>
<td>2729/1138</td>
<td>892/899</td>
<td>4828/4741</td>
<td>5128 / 5123</td>
</tr>
<tr>
<td>Age (yr)</td>
<td>53.2±8.6/53.4±8.6</td>
<td>60.5±9.0/60.3±9.0</td>
<td>66.0±9.0/66.0±9.0</td>
<td>62.2±6.8/62.2±6.8</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>27.5±5.1/27.8±5.5</td>
<td>31.3±5.3/31.2±5.0</td>
<td>28.0±5.0/28.0±5.0</td>
<td>9.8±7.1/10.1±7.2</td>
</tr>
<tr>
<td>Diabetes duration (yr)</td>
<td>Newly diagnosed</td>
<td>11.5±8.0/11.5±7.0</td>
<td>7.9±4.8/7.9±5.4</td>
<td>9.8±7.1/10.1±7.2</td>
</tr>
<tr>
<td>Achieved Hb1c (%)</td>
<td>7.6(6.2-8.2)/7.9(6.9-8.8)</td>
<td>6.9(6.6-7.5)/8.4(8.0-9.5)</td>
<td>6.3(5.9-6.9)/7.0(6.4-7.9)</td>
<td>6.3(5.9-7.0)/7.6(7.0-8.2)</td>
</tr>
<tr>
<td>Follow-up (yr)</td>
<td>10.0 (7.7-12.4)</td>
<td>5.6 (3.3-7.5)</td>
<td>5.0 (4.3-5.8)</td>
<td>3.5 (3.4-5.6)</td>
</tr>
</tbody>
</table>

Vascular and mortality outcomes: HR or percentage of subjects with the outcome of interest

<table>
<thead>
<tr>
<th>Microvascular</th>
<th>HR (95% CI)</th>
<th>T vs. C</th>
<th>% T vs. C</th>
<th>HR (95% CI)</th>
<th>T vs. C</th>
<th>HR (95% CI)</th>
<th>T vs. C</th>
</tr>
</thead>
<tbody>
<tr>
<td>Microalbuminuria</td>
<td>0.67 (0.53-0.86)</td>
<td>9.7/13.2</td>
<td>0.91 (0.85-0.98)</td>
<td>0.79 (0.69-0.90)</td>
<td>0.85 (0.77-0.94)</td>
<td>0.90 (0.82-0.99)</td>
<td></td>
</tr>
<tr>
<td>Macroalbuminuria</td>
<td>0.66 (0.39-1.10)</td>
<td>2.9/5.1</td>
<td>0.71 (0.57-0.85)</td>
<td>0.69 (0.55-0.85)</td>
<td>0.72 (0.61-0.84)</td>
<td>0.69 (0.55-0.85)</td>
<td></td>
</tr>
<tr>
<td>Doubling of s. creat.</td>
<td>0.26 (0.07-0.91)</td>
<td>8.8/8.8</td>
<td>1.15 (0.82-1.63)</td>
<td>1.07 (1.01-1.13)</td>
<td>1.04 (0.99-1.10)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Retinopathy</td>
<td>0.79 (0.69-1.00)</td>
<td>17.0/22.1</td>
<td>0.98 (0.94-1.04)</td>
<td>0.95 (0.87-1.04)</td>
<td>0.93 (0.87-1.00)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Macrovascular</td>
<td>HR (95% CI)</td>
<td>T vs. C</td>
<td>HR (95% CI)</td>
<td>T vs. C</td>
<td>HR (95% CI)</td>
<td>T vs. C</td>
<td></td>
</tr>
<tr>
<td>MI</td>
<td>0.84 (0.71-1.00)</td>
<td>0.88 (0.74-1.05)</td>
<td>0.94 (0.84-1.06)</td>
<td>0.76 (0.62-0.92)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stroke</td>
<td>1.11 (0.81-1.51)</td>
<td>1.30 (0.92-1.66)</td>
<td>0.86 (0.65-1.13)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mortality</td>
<td>HR (95% CI)</td>
<td>T vs. C</td>
<td>HR (95% CI)</td>
<td>T vs. C</td>
<td>HR (95% CI)</td>
<td>T vs. C</td>
<td></td>
</tr>
<tr>
<td>Death from all cause</td>
<td>0.94 (0.80-1.10)</td>
<td>1.07 (0.81-1.42)</td>
<td>0.93 (0.83-1.06)</td>
<td>1.22 (1.01-1.46)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Death from CVD</td>
<td>0.94 (0.68-1.30)</td>
<td>1.32 (0.81-2.14)</td>
<td>0.88 (0.74-1.04)</td>
<td>1.35 (1.04-1.76)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Legend: Data are number, mean ± SD, median (interquartile range), percentage, or HR (95%CI) in tight control (T) group vs. conventional control (C) group. * p < 0.05. † Composite CV events. ‡ Outcomes at 3.5 years. § Outcomes at 5 years, after transition from T to C glycemic control in the intensive-therapy group. Abbreviations: UKPDS - UK Prospective Diabetes Study, VADT - Veterans Affairs Diabetes Trial, ADVANCE - Action in Diabetes and Vascular Disease, ACCORD - Action to Control Cardiovascular Risk in Diabetes, BMI - body mass index, HbA1c - glycated hemoglobin, MI - myocardial infarction, HR - hazard ratio, CI - confidence interval, SD - standard deviation, s. creat. - serum creatinine.
and 3'UTR of the VEGF gene were strongly associated with elevated risk of DR [123]. Anti-angiogenic VEGF inhibitors, including bevacizumab and pegaptanib, have been used in the treatment of proliferative DR in small trials. In the short term, the proportion of anti-VEGF-treated patients with complete regression of retinal neovascularization was significantly higher than in the control groups [124, 125]. Polymorphism in the retinoid-X receptor (RXR) gamma gene has also been associated with DR (OR = 2.388; 95% confidence interval = 1.17-4.875) in Asians with T2D [126]. Polymorphisms in the regulatory region of the aldose reductase (ALR2) gene (encoding the rate-limiting enzyme of the polyol pathway) were associated with susceptibility to DN and DR [114, 127]. However, the impacts of these genetic risk factors were modest, and some studies yielded inconsistent findings [128, 129].

The role of hyperglycemic environmental exposure in vascular complications

The strong relationship between hyperglycemia and diabetic vascular complications is the legacy of diabetes and its medical management. Hyperglycemia induces endothelial dysfunction through direct toxic effects (hyperosmolality and advanced glycation end products), and through derangements in multiple interrelated intracellular signaling pathways (e.g., aldose reductase pathway, advanced glycation end product pathway, reactive oxygen intermediate pathway, and protein kinase C pathway) [130]. In summary, these alterations result in an amplification of endothelial proliferative factors (insulin-like growth factor 1, transforming growth factor β, and vascular endothelial growth factor), activation of the NF-κB pathway, and vascular inflammation; all of which underlie vascular diseases in diabetes.

Although glycemic control early in the course of diabetes reduces vascular complication rates, end-organ vascular complications still occur at high frequencies. This observation led to the theory of persistent epigenetic changes that contribute to diabetic vascular complications long after the occurrence of the hyperglycemic events because of hyperglycemia-associated histone modifications. These modifications persist after restoration of normoglycemia, a process termed ‘hyperglycemic memory’ or ‘legacy effect’ [131]. Histone modifications (altered acetylation, methylation, phosphorylation, and/or sumoylation) control transcription expression, cell cycle regulation, and cellular differentiation [132, 133]. In vitro studies in endothelial cell lines demonstrated that cells exposed to hyperglycemia underwent histone modification, activation of multiple transcription factors [134], increased H3K4 methylation at the NF-κB-p65 promoter, enhanced expression of NF-κB-p65, and increased NF-κB-driven pro-inflammatory gene expression [135].

Importantly, the duration of hyperglycemia can differentially impact the susceptibility to diabetes-related microvascular and macrovascular complications. This conclusion is based on results from several large randomized intensive vs. conventional therapy trials for blood sugar control in patients with T2D. The design and results of four landmark trials (UKPDS, ADVANCE, ACCORD, and VADT) are summarized in Table 2. In UKPDS, ADVANCE, and ACCORD, protection from microvascular disease (DR and/or albuminuria as surrogate of DN) was achieved with tight glycemic control [136-139]. In VADT, no clear benefit of glycemic control on microvascular complications was detected. However, this study had fewer patients with long diabetes durations prior to enrollment and a shorter follow-up period [140].

The relationship between good glycemic control and protection from macrovascular complications has been critically questioned. In ADVANCE and VADT, significant declines in the incidence rates of cardiovascular disease through improved glucose control could not be detected [137, 140]. The only study showing declines in cardiovascular events through tight glucose control was UKPDS [136]. More surprising were the ACCORD results, with a higher mortality observed in the intensive control group [141]. The negative impact of tight glycemic control was maintained in the long term follow-up, further suggesting the presence of a glycemic memory phenomenon in diabetic vascular complications [142].

The different macrovascular complication rates may be caused by important design differences between ACCORD, ADVANCE, and UKPDS (Table 2). ACCORD and ADVANCE enrolled patients with longstanding diabetes (mean diabetes duration 8-12 years) and shorter follow-up durations (mean follow-up 5 years), as opposed to newly diagnosed subjects with T2D and 10 year follow-up in UKPDS. Also, baseline burdens of cardiovascular disease risk factors, medication regimens for diabetes control, rates of hypoglycemia, blood pressure and lipid control, and definitions used for the primary vascular outcomes were heterogeneous.
across these studies, and could underlie the variability of results. Despite the problems associated with the different study designs, the results provided support for the 'legacy effect' in the case of macrovascular complications. Persistent hyperglycemia induces deleterious consequences in the vasculature which perpetuate even in the event of subsequent improvements in glucose control. These results underscore the need for early detection and appropriate therapeutic intervention in diabetes, with the need for moderate glycemic control (HbA1c 6.2-7%), as opposed to tight control (HbA1c ≤ 6.1%).

Concluding remarks

The clinical and pathophysiologic spectrum of T2D has expanded greatly with the detection of genetic determinants through high-throughput genetic studies. Although a susceptible genetic background appears to be necessary for the development of overt diabetes, it is only fully sufficient in rare Mendelian forms of diabetes. Western lifestyles, obesity, dietary supplements, exposure to organic pollutants, and glycemic control serve as examples of non-genetic environmental factors which ultimately interact with risk alleles in susceptibility genes to initiate the common forms of T2D and diabetic vascular complications. As opposed to the presently immutable and complex genetic heritability, exogenous risk factors are amendable by intervention, which may save a considerable proportion of patients from development of T2D and vascular complications.

GWAS results are used as a platform for gene-environment and gene-gene interaction studies. In the future, new avenues will be developed to reveal the intricate genetic architecture of complex diseases by performing targeted genome sequencing, whole-exome sequencing, or whole genome sequencing. The current data reflect decades of functional work to decipher the underlying biology. It is hoped that this research will ultimately translate into new therapeutic modalities.

Disclosure: The authors report no conflict of interests in relation to this work.

References

14. Meigs JB, Panhuysen CI, Myers RH, Wilson PW, Cupples LA. A genome-wide scan for loci linked to plasma levels of glucose and HbA1c in a community-based sample


17. Ng MC, So WY, Lam VK, Cochram CS, Bell GI, Cox NJ, Chan JC. Genome-wide scan for metabolic syndrome and related quantitative traits in Hong Kong Chinese and confirmation of a susceptibility locus on chromosome 1q21-q25. Diabetes 2004. 53:2676-2683.


70. Facchinetti F, Coulston AM, Reaven GM. Relation be-


84. Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nat ature 2007; 447:661-678.


118. Sobrin L, Green T, Sim X, Jensen RA, Tai ES, Tay


